Last 48 quarters of trend data · Healthcare · Big Pharma
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.69 | 15.85 | 59.57 | 16.04 | 39.55 | 11.01 | 13.71 | 12.42 | 42.27 | — | 17.19 | 21.43 | 54.50 | 12.59 | 11.14 | 12.35 | 11.87 | 1.39 | 25.91 | 12.38 | 30.63 |
| — | +43.9% | +334.4% | +29.2% | -6.4% | — | -20.2% | -42.1% | -22.4% | — | +54.3% | +73.5% | +359.1% | +806.7% | -57.0% | -0.2% | -61.2% | -91.6% | +82.2% | -25.1% | +13.2% | |
| P/S Ratio | 2.26 | 2.78 | 3.17 | 3.68 | 2.91 | 2.59 | 2.47 | 2.67 | 2.16 | 2.60 | 2.52 | 2.99 | 2.37 | 2.29 | 2.54 | 2.61 | 2.44 | 1.92 | 3.19 | 3.08 | 2.36 |
| — | +7.4% | +28.1% | +38.2% | +34.6% | -0.5% | -1.8% | -11.0% | -8.9% | +13.8% | -1.0% | +14.5% | -2.8% | +19.1% | -20.4% | -15.1% | +3.3% | -34.3% | -7.3% | +27.1% | +11.1% | |
| P/B Ratio | 4.87 | 5.31 | 6.24 | 4.89 | 6.29 | 4.17 | 4.01 | 4.55 | 5.36 | 6.20 | 4.56 | 5.28 | 4.68 | 4.84 | 4.72 | 5.20 | 7.12 | 6.18 | 3.22 | 6.66 | 3.11 |
| — | +27.1% | +55.4% | +7.6% | +17.4% | -32.7% | -12.0% | -13.8% | +14.5% | +28.1% | -3.4% | +1.5% | -34.3% | -21.7% | +46.7% | -22.0% | +129.0% | +134.1% | +19.3% | +168.6% | +19.1% | |
| P/FCF | 11.11 | 10.16 | 12.06 | 40.27 | 16.97 | 8.51 | 13.48 | 28.74 | 14.68 | 15.89 | 29.56 | 25.16 | 6.29 | 10.86 | 23.62 | — | 14.49 | 13.40 | 18.29 | 11.23 | 5.35 |
| — | +19.3% | -10.5% | +40.1% | +15.6% | -46.4% | -54.4% | +14.3% | +133.2% | +46.3% | +25.2% | — | -56.6% | -18.9% | +29.1% | — | +170.8% | +121.0% | +3.5% | — | +13.9% | |
| EV / EBITDA | 9.94 | 9.06 | 43.04 | 12.07 | 12.51 | 8.10 | 7.68 | 8.08 | 18.81 | 21.11 | 10.62 | 13.13 | 19.97 | 9.50 | 9.28 | 8.72 | 9.65 | 9.41 | 13.45 | 10.26 | 23.16 |
| — | +11.8% | +460.3% | +49.4% | -33.5% | -61.6% | -27.6% | -38.5% | -5.8% | +122.2% | +14.4% | +50.6% | +107.0% | +1.0% | -31.0% | -15.0% | -58.3% | -19.7% | -11.6% | -16.9% | +195.4% | |
| EV / EBIT | 10.77 | 11.67 | 56.67 | 14.39 | 25.46 | 10.29 | 11.80 | 10.81 | 29.49 | 109.39 | 14.53 | 17.60 | 44.72 | 12.17 | 11.08 | 11.25 | 12.09 | 16.67 | 24.42 | 12.10 | 32.81 |
| — | +13.4% | +380.2% | +33.1% | -13.6% | -90.6% | -18.8% | -38.6% | -34.1% | +798.5% | +31.2% | +56.5% | +269.8% | -27.0% | -54.6% | -7.0% | -63.1% | -13.8% | +11.0% | -18.0% | +30.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.4% | 74.5% | 73.1% | 75.4% | 69.2% | 73.6% | 72.9% | 74.2% | 68.5% | 70.1% | 73.1% | 73.2% | 70.0% | 72.1% | 73.1% | 72.0% | 69.7% | 69.1% | 68.6% | 62.2% | 61.4% |
| — | +1.2% | +0.2% | +1.6% | +1.0% | +5.0% | -0.3% | +1.3% | -2.1% | -2.8% | +0.0% | +1.7% | +0.4% | +4.4% | +6.5% | +15.8% | +13.5% | -0.8% | -3.0% | -6.5% | -3.7% | |
| Operating Margin | 25.5% | 28.9% | 5.7% | 30.1% | 17.5% | 30.3% | 25.3% | 29.5% | 8.6% | 2.4% | 20.9% | 20.2% | 7.1% | 23.9% | 29.8% | 30.0% | 25.3% | 15.2% | 15.6% | 31.9% | 9.4% |
| — | -4.7% | -77.4% | +1.9% | +103.8% | +1186.1% | +21.3% | +45.7% | +20.5% | -90.1% | -30.0% | -32.4% | -71.9% | +57.3% | +91.2% | -6.1% | +169.6% | -26.9% | -28.6% | +39.7% | -22.6% | |
| Net Margin | 17.5% | 17.4% | 5.2% | 22.8% | 7.4% | 23.6% | 18.1% | 21.6% | 5.1% | -0.7% | 14.9% | 14.2% | 4.3% | 18.0% | 22.6% | 21.4% | 19.8% | 138.2% | 12.1% | 25.1% | 7.9% |
| — | -26.3% | -71.4% | +5.4% | +44.7% | +3353.5% | +21.4% | +52.1% | +17.3% | -104.0% | -34.2% | -33.7% | -78.1% | -87.0% | +87.1% | -14.5% | +151.9% | +569.6% | -49.4% | +73.3% | +1.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 39.4% | 8.6% | 2.2% | 8.9% | 3.4% | 9.8% | 7.7% | 10.6% | 3.1% | -0.4% | 6.9% | 6.3% | 2.2% | 9.5% | 11.0% | 12.4% | 14.7% | 58.1% | 4.1% | 8.5% | 2.6% |
| — | -12.6% | -71.9% | -15.6% | +9.8% | +2720.2% | +12.5% | +66.9% | +41.3% | -104.0% | -37.7% | -48.8% | -85.0% | -83.7% | +168.5% | +44.9% | +472.9% | +1156.5% | -13.4% | +128.6% | +4.7% | |
| ROA | 9.5% | 2.3% | 0.6% | 2.4% | 0.9% | 2.5% | 1.8% | 2.4% | 0.7% | -0.1% | 1.6% | 1.4% | 0.5% | 2.0% | 2.2% | 2.2% | 2.3% | 12.3% | 0.9% | 1.9% | 0.7% |
| — | -6.7% | -66.7% | +2.4% | +25.7% | +2887.0% | +13.6% | +68.0% | +50.5% | -104.5% | -27.4% | -37.6% | -79.6% | -84.2% | +145.2% | +16.2% | +226.3% | +857.9% | -31.3% | +96.2% | +11.3% | |
| ROIC | 22.1% | 5.3% | 1.0% | 4.7% | 3.2% | 4.9% | 4.1% | 5.4% | 2.0% | 0.5% | 3.5% | 3.1% | 1.2% | 3.9% | 4.3% | 4.9% | 4.9% | 2.3% | 2.0% | 3.7% | 1.2% |
| — | +8.8% | -76.7% | -13.0% | +60.9% | +963.9% | +17.2% | +70.6% | +67.1% | -88.0% | -18.4% | -36.0% | -75.6% | +66.2% | +117.8% | +31.1% | +315.8% | +34.0% | +22.0% | +70.3% | -16.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.11 | 1.29 | 1.06 | 1.09 | 1.11 | 1.13 | 1.21 | 1.35 | 1.30 | 1.19 | 1.23 | 1.34 | 1.41 | 1.65 | 1.77 | 1.85 | 2.08 | 2.54 | 0.98 | 2.08 | 1.13 |
| — | +14.5% | -12.2% | -19.0% | -14.4% | -5.6% | -1.7% | +0.5% | -7.8% | -27.7% | -30.3% | -27.3% | -32.3% | -34.9% | +80.8% | -11.1% | +83.5% | +115.5% | -17.3% | +66.6% | -13.2% | |
| Debt / EBITDA | 1.66 | 7.27 | 25.68 | 9.12 | 7.73 | 7.17 | 7.47 | 7.83 | 15.33 | 14.09 | 9.37 | 11.01 | 19.21 | 10.06 | 10.53 | 9.50 | 9.09 | 11.50 | 13.44 | 10.19 | 25.96 |
| — | +1.3% | +243.7% | +16.5% | -49.6% | -49.1% | -20.3% | -28.9% | -20.2% | +40.0% | -11.0% | +15.9% | +111.4% | -12.5% | -21.7% | -6.8% | -65.0% | -23.8% | -30.5% | -42.1% | +129.2% | |
| Current Ratio | 0.82 | 0.86 | 0.82 | 0.79 | 0.82 | 0.84 | 0.87 | 0.87 | 0.78 | 0.81 | 0.82 | 0.87 | 0.88 | 0.95 | 0.88 | 0.95 | 0.91 | 0.97 | 1.43 | 0.91 | 0.79 |
| — | +3.3% | -6.0% | -8.8% | +4.5% | +3.7% | +5.3% | +0.1% | -11.5% | -15.0% | -5.8% | -9.0% | -2.8% | -1.8% | -38.9% | +4.6% | +15.4% | +18.7% | +74.4% | -0.3% | -13.7% | |
| Quick Ratio | 0.54 | 0.56 | 0.52 | 0.52 | 0.54 | 0.55 | 0.57 | 0.58 | 0.52 | 0.53 | 0.54 | 0.58 | 0.62 | 0.70 | 0.63 | 0.69 | 0.68 | 0.74 | 1.31 | 0.68 | 0.54 |
| — | +1.8% | -8.0% | -10.8% | +3.7% | +3.6% | +6.2% | +0.1% | -16.3% | -24.7% | -14.4% | -16.5% | -8.9% | -5.4% | -52.2% | +1.3% | +25.8% | +38.9% | +149.1% | +12.8% | -15.4% | |
| Interest Coverage | 11.77 | 11.73 | 2.95 | 13.84 | 6.46 | 15.71 | 11.26 | 14.01 | 4.91 | 1.41 | 9.59 | 9.16 | 1.94 | 10.84 | 11.74 | 10.39 | 7.14 | 6.06 | 5.39 | 11.21 | 4.74 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GSK stock.
GSK plc's current P/E is 17.7x. The average P/E over the last 4 quarters is 32.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
GSK plc's current operating margin is 25.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking GSK plc's business trajectory between earnings reports.